Lannett (LCI) 4.55 0.05

Lannett Co., Inc.
(LCI) 4.55 0.05

Last Trade:	4.13	Day Range:	4.04 - 4.22
Trade Time:	06:05PM	52wk Range:	3.41 - 5.89
Prev. Close:	4.08	Market Cap:	117.15M
Open:	4.06	Div Yield:	0
Volume:	43126	PE:
EPS:	0.02

The Latest On LCI

Lannett Receives FDA Approval for ANDA Supplement for Phentermine HCL Capsules, 15 mg 1/31/12 9:05am

Lannett Receives FDA Approval for Hydrochlorothiazide Capsules, 12.5 mg 1/30/12 9:15am

Lannett Receives Letter from NYSE Amex Regarding Timely Notice of Record Date for 2012 Annual Shareholders Meeting 1/6/12 5:31pm

Lannett Reaches Special Protocol Assessment Agreement with FDA for Cocaine HCl Phase III Trial 1/4/12 12:40pm

Lannett Receives FDA Approval for Triamterene with Hydrochlorothiazide 37.5/25mg Capsules 12/12/11 3:44pm

Lannett Receives FDA Approval for Diethylpropion HCl Extended Release Tablets, 75 mg 10/24/11 1:36pm

Mylan Laboratories Earnings Preview: Analysts Expect Higher EPS, Revenue 10/21/11 4:07pm

Lannett Launches Three Recently Approved Products 10/14/11 8:01am

Lannett Receives FDA Approval for Loxapine Capsules 9/27/11 8:02am

Lannett Company CEO Purchases 20,467 Shares of Company's Stock 9/12/11 4:18pm

Earnings Scheduled For September 7 9/7/11 4:02am

Lannett Appoints Jeffrey Farber as Vice Chairman 8/16/11 8:10am

Lannett Receives FDA Approval for ANDA Supplement for Phentermine HCL Capsules, 15 mg 1/31/12

Lannett Receives FDA Approval for Hydrochlorothiazide Capsules, 12.5 mg 1/30/12

Lannett Receives Letter from NYSE Amex Regarding Timely Notice of Record Date for 2012 Annual Shareholders Meeting 1/6/12

Lannett Reaches Special Protocol Assessment Agreement with FDA for Cocaine HCl Phase III Trial 1/4/12

Lannett Receives FDA Approval for Triamterene with Hydrochlorothiazide 37.5/25mg Capsules 12/12/11

Lannett Receives FDA Approval for Diethylpropion HCl Extended Release Tablets, 75 mg 10/24/11

Mylan Laboratories Earnings Preview: Analysts Expect Higher EPS, Revenue 10/21/11

Lannett Launches Three Recently Approved Products 10/14/11

Lannett Receives FDA Approval for Loxapine Capsules 9/27/11

Lannett Company CEO Purchases 20,467 Shares of Company's Stock 9/12/11

Earnings Scheduled For September 7 9/7/11

Lannett Appoints Jeffrey Farber as Vice Chairman 8/16/11

Mylan Laboratories Earnings Preview: Analysts Expect Higher EPS, Revenue 10/21/11

FDA PDUFA Dates Scheduled for Tomorrow: LCI, DRRX, and PITE 6/22/11

Lannett Nears FDA Approval; Awaits Facility Clearance (LCI) 2/1/11

Oppenheimer Initiates Coverage Of LCI With Outperform 3/30/11

Oppenheimer Initiates Coverage Of Lannett At Outperform, $7 PT (LCI) 3/30/11

Trade LCI
NOW!

Partner Headlines

Lannett Company Inc Reports Operating Results (10-Q) 2/8/12

Lannett Company Inc Reports Operating Results (10-Q) 11/4/11

Lannett Enters Oversold Territory - Tale of the Tape 4/11/11

Press Releases

MillerCoors Activates Consumers and Communities on Water Stewardship with Fourth Annual Grant Competition 2/21/12 PRWeb

MTNW Announces NSF Award to Retrofit US Coast Guard Icebreakers Healy & Polar Sea 2/21/12 PRWeb

Gypsum Association Commissions Athena Institute to Conduct Extensive LCA Study 2/16/12 PRWeb

Get the latest LCI stock news on the web. Get the latest stock quotes and much more - Benzinga is the source for Lannett Co., Inc. stock price.

Lannett Co., Inc. by YCharts

Lannett (LCI) 4.55 0.05

Quotes

Analysis

Twitter

Ownership

Earnings

The Latest On LCI

From Benzinga's Newsdesk

Benzinga's News Delivered Free

Latest from Premium

Brain Trust

Popular Channels

Tools & Features

About Benzinga

Social